Treatment Effects of Two Pharmaceutical Skin Care Creams for Xerotic Feet Among Persons with Diabetes
A Superiority Study Comparing Two Pharmaceutical Skin Care Creams Containing Different Humectants with a Non-humectant Containing Skin Care Cream for the Treatment of Xerotic Foot of Persons with Diabetes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Tautgirdas Ruzgas, Professor
- Phone Number: +46406657431
- Email: tautgirdas.ruzgas@mau.se
Study Locations
-
-
Skane
-
Malmö, Skane, Sweden, 21432
- Recruiting
- Malmö University
-
Contact:
- Tautgirdas Ruzgas professor
- Phone Number: 46-4057431
- Email: tautgirdas.ruzgas@mau.se
-
Contact:
- Johan Engblom professor
- Phone Number: 46-4057483
- Email: johan.engblom@mau.se
-
Contact:
- Christine Kumlien, professor
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Persons above 18 years of age diagnosed with diabetes mellitus, both type I and II, with self-experienced dry skin.
- Dry skin on both feet with a Xerosis Severity Scale (XSS) score between two to six. No more than one XSS score in difference between the subjects' feet.
- Ability to understand sufficient Swedish language to complete the necessary forms and understand the procedure of the study.
Exclusion Criteria:
- Known sensibility to any of the ingredients in the products.
- Other diagnosed skin disease on the feet.
- Active lesions on either foot.
- Treatment with local medications, including topical moisturizers or keratolytic agents on the feet, within two weeks before the beginning of the study.
- Potential study subjects judged unable to comply with treatment schedule and study specific information.
- Female of childbearing potential that do not use effective medically accepted contraception.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Canoderm
Topical on feet twice a day
|
humectant
|
|
Experimental: Oviderm
Topical on feet twice a day
|
humectant + antimicrobial
|
|
Active Comparator: Decubal
Topical on feet twice a day
|
Non-humectant
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Xerosis Severity
Time Frame: 4 weeks
|
Change in Xerosis Severity (Scale scores 0 - 6, 6 is the worst)
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Transepidermal water loss
Time Frame: 4 weeks
|
Trans epidermal water loss (TEWL) (grams per square meter per hour)
|
4 weeks
|
|
Skin resistance
Time Frame: 4 weeks
|
Skin resistance in Ohms (Ω)
|
4 weeks
|
|
Skin Capacitance
Time Frame: 4 weeks
|
Skin Capacitance in Farads (F)
|
4 weeks
|
|
Skin pH
Time Frame: 4 weeks
|
Skin pH (5-8)
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Christine Kumlien, Professor, Malmö University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2022-500907-27-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.